Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects
Open Access
- 9 June 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (11), 2439-2450
- https://doi.org/10.1182/bloodadvances.2019001319
Abstract
Pharmacological inhibitors of Bruton tyrosine kinase (BTK) have revolutionized treatment of B-lymphocyte malignancies and show great promise for dampening autoimmunity. The predominant BTK inhibitors tether irreversibly by covalently binding to cysteine 481 in the BTK catalytic domain. Substitution of cysteine 481 for serine (C481S) is the most common mechanism for acquired drug resistance. We generated a novel C481S knock-in mouse model and, using a battery of tests, no overt B-lymphocyte phenotype was found. B lymphocytes from C481S animals were resistant to irreversible, but sensitive to reversible, BTK inhibitors. In contrast, irreversible inhibitors equally impaired T-lymphocyte activation in mice, mimicking the effect of treatment in patients. This demonstrates that T-lymphocyte blockage is independent of BTK. We suggest that the C481S knock-in mouse can serve as a useful tool for the study of BTK-independent effects of irreversible inhibitors, allowing for the identification of novel therapeutic targets and pinpointing potential side effects.Keywords
This publication has 66 references indexed in Scilit:
- Differential Evolutionary Wiring of the Tyrosine Kinase BtkPLOS ONE, 2012
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Blood, 2011
- Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross‐regulation of cytokine production and T‐cell fatesThe FEBS Journal, 2011
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences of the United States of America, 2010
- Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell developmentGenes & Development, 2009
- Functional replacement of Drosophila Btk29A with human Btk in male genital development and survivalFEBS Letters, 2005
- Spontaneous Autoimmunity in 129 and C57BL/6 Mice—Implications for Autoimmunity Described in Gene-Targeted MicePLoS Biology, 2004
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- Defective B cell development and function in Btk-deficient miceImmunity, 1995
- The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stagesEuropean Journal of Immunology, 1993